brain upon injury [2, 3] . However, even the human brain holds substantial potential for at least partial compensation and thus functional repair by a process called functional neuroplasticity: for example, motor or sensory skills that are lost in the course of an ischemic stroke can be -with time and training -taken over by other brain regions that had not been involved in those motor or sensory functions before the injury [4] .
Introduction
The brain is at constant risk to be hurt and impaired in its function by traumatic injuries or chronic diseases, associated with inflammation and neurodegeneration. In contrast to many other organs and tissues such as the skin or liver in mammals that retain the capacity to regenerate and regain at least partially lost functions, the brain cannot simply regrow injured areas that become functionally connected to the unharmed regions of the brain [1] . The inability of the mammalian brain to regenerate has been associated with its complex functions and the required need for stability, which is in contrast to lower species such as certain invertebrates that retain the capacity to regrow substantial parts of the adult brain and ii) differentiates into a neuron [6] . It is now fully accepted that new neurons are generated throughout life in mammals [7] .
However, there seem to be substantial species differences: whereas in rodents (and also non-human primates) a substantial number of NSCs persist in the subventricular zone (SVZ) that generate new cells migrating via the rostral migratory stream (RMS) towards the olfactory bulb (OB) where they differentiate into different types of olfactory neurons, this neurogenic system seems to be absent/inactive in the adult human brain [8] [9] [10] [11] ; but see also [12] . In contrast, new neurons are born throughout life in the hippocampal dentate gyrus (DG) both in rodents and primates including humans [13] [14] [15] . The hippocampus is required for certain forms of learning and in simple terms serves as a filter station that is required for many types of memory and determines which of these memories are transferred into long-term storage [16] . Furthermore, the hippocampus is involved in the regulation of mood [17] .
In the DG, NSCs reside in the subgranular zone where they divide and generate cells that differentiate into excitatory, glutamatergic granule cells and that integrate into the DG over the course of several weeks [18, 19] . This process, called adult hippocampal neurogenesis, is important for proper hippocampal function and critically involved in dentate computation of incoming information [20] [21] [22] . Thus, the main purpose of neurogenesis in the DG is certainly not to serve as a backup system for repair in the case of injury. Neurogenesis is required for normal brain function.
However, failing or altered neurogenesis has been associated with several neuropsychiatric diseases. For example, it has been shown that stress, one of the key components in the etiology of affective disorders, substantially decreases the number of newborn neurons [23] . Furthermore, it has been shown that certain antidepressants such as selective serotonin-reuptake inhibitor (SSRI; e.g., fluoxetine) enhance neurogenesis and require proper neurogenesis for their antidepressant action, at least in rodents [24] [25] [26] . Thus, altered neurogenesis may participate in the disease process of affective disorders such as major depression. Given this, novel compounds that specifically target the activity of NSCs or later steps of neuronal differentiation/integration may have beneficial effects in the treatment of affective disorders.
However, neurogenesis cannot only be reduced, but there are also circumstances where the integration of newborn granule cells is affected: epileptic seizures induce the ectopic generation of granule cells that do not show proper integration into the DG circuit [27, 28] . They extend aberrant processes and show aberrant migration, for example into the hilus of the DG. Thus, it has been speculated that seizure-induced, aberrant neurogenesis may interfere with proper circuit function in epilepsy patients and may also contribute to the process of epileptogenesis [29] . Targeting NSCs and the neurogenic process in depression or epilepsy may hold the potential to ameliorate disease symptoms or to attenuate disease progression.
Normalizing or enhancing neurogenesis in the context of diseases affecting this process is only one aspect how the neurogenic permissiveness of adult NSCs may be useful to ameliorate brain function. Clearly, the finding that NSCs persist in the adult brain has also opened new possibilities for targeted induction of neurogenesis in the adult brain. When can this be helpful? Many degenerative diseases of the nervous system are associated with substantial neuronal cell death in the chronic phase of the disease although neural death and degeneration also affects early and subclinical phases of many brain diseases. Even though novel treatment op- tions appear on the horizon that for example attenuate disease progression in Alzheimer's disease (AD) by reducing the amyloid load in affected patients [30, 31] , it is also clear that neurons that are lost at the stage of diagnosis/treatment will be chronically lost. Thus, enhancing neurogenesis in diseases such as AD that dramatically affect hippocampal function may be useful to improve brain function by providing new neurons for the injured hippocampus. If enhanced neurogenesis is efficient to enhance cognitive function in humans remains unclear but is certainly an exciting area where the combination of approaches to attenuate disease progression (e.g., lowering amyloid load) together with regenerative strategies (i.e., enhancing neurogenesis) may turn out to be effective and clinically relevant in the future [32] .
As outlined above, neurogenesis in the SVZ/OB seems to extremely low or completely absent in the human brain [11] . However, there is evidence that NSCs may be also retained in the human SVZ but that they are just not generating cells that migrate to the OB [10, 12, 33] . Interestingly, it has been recently shown that neuroblasts are present also in the adult human SVZ and neighboring striatum and that they are able to generate new striatal interneurons throughout life in the human brain [34] . Strikingly, this type of neurogenesis appears to be substantially lower in patients with Huntington's disease (HD), suggesting that approaches to enhance striatal neurogenesis may represent a novel therapeutic approach in HD [34] . Thus, enhancing neurogenesis in the SVZ may also hold the potential for repair in the human brain. Basic research in the SVZ aiming to understand how NSCs become activated may turn out to be helpful to induce neurogenesis also in the human SVZ [35] .
NSCs may not represent the only source for neurons generated in the human brain. Whereas in the rodent SVZ NSCs are capable to respond to injuries such as ischemic strokes that lesion the neighboring striatum resulting in the enhanced generation and subsequent striatal migration of new neurons generated in the SVZ, strokes in human seem not to directly affect neurogenesis in the SVZ [36] [37] [38] . However, recent data in mice showed that local astroglial cells carry a latent neurogenic program (e.g., being capable to generate neuronal cells) that becomes activated upon ischemic stroke [39] . Mechanistically, the latent neurogenic program depends on Notch signaling, providing an entry point how this novel route for neurogenesis may also be targeted in human diseases such as stroke [39] .
Taken together, the finding that NSCs remain active in the adult mammalian brain and that new neurons are generated throughout life has opened novel approaches to either ameliorate disease symptoms or to truly induce neurogenesis in areas where neurons are lost in the context of acute or chronic degenerative disease.
Generating Neuronal and Glial Cells at the Site of Injury
Apart from strategies to utilize the neurogenic potential of endogenous NSCs to locally generate new neuronal cells, an alternative approach has been to ectopically induce the generation of neuronal (and glial) cells to support brain repair [40, 41] . This is based on a vast amount of data from basic research aiming to characterize the transcriptional programs that guide neurogenesis during embryonic development and in the adult neurogenic niches. The idea was to use this knowledge to redirect the fate of newborn cells towards a neuronal fate (or any desired cell fate). Thus, key neurogenic transcription factors used alone or in combinations with other fate determinants have been successfully used in the rodent brain to induce functional neurogenesis, for example after experimental lesions of the cortex [42] . Starting cells that were targeted -mostly by retroviral vectors expressing key transcription factors -include astroglial (i.e., astrocytes) and oligodendroglial (i.e., oligodendrocyte precursors) cells that were directed to generate neurons or other required cell types such as oligodendrocytes in the context of demyelinating disease [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] . So far the generation of several distinct neuronal subtypes has been achieved. This is obviously important to replace the exact neuronal subtype that is lost in the respective diseases. One example, where neuronal cell replacement may turn out to be feasible is Parkinson's disease (PD) where mostly dopaminergic neurons are lost. Current attempts aim to generate dopaminergic neurons by targeted overexpression of single transcription factors or cocktails of previously identified key regulators within the striatum (the target area of most dopaminergic neurons extending their axons) or directly in the substantia nigra (where dopaminergic neurons are lost in PD) [56, 58] .
Notably, the tailored generation of cells for brain repair is not restricted to neuronal cells. Clearly, a variety of brain diseases are associated with a loss of function of glial cells. Of particular interest are oligodendrocytes that form myelin sheets around axons, which are required for proper neuronal function. Impaired myelin function and subsequent demyelination is a common feature of a variety of diseases ranging from multiple sclerosis (MS) to epilepsy [59, 60] . Death of myelinating oligodendrocytes leads ultimately to neuronal loss and functional impairments. In the context of MS, immune cells attack myelinating oligodendrocytes and subsequently kill them. Whereas the therapeutic possibilities and treatment options of the initial inflammatory phase of the disease have substantially improved over the last decades, there is still no regenerative approach available that may help to induce remyelination and thus prevent functional loss that is associated with secondary neuronal cell death [59, 61] . Thus, inducing the formation of myelinating oligodendrocytes either by activating oligodendrocytes precursor cells or by reprogramming other neural cells into myelinating oligodendrocytes may represent a promising approach [62, 63] . In this context, it has also been shown that NSCs in the DG that do not generate oligodendrocytes under normal conditions retain the potential for oligodendrocyte differentiation and can be redirected to adopt an oligodendroglial fate [64, 65] . Those newborn oligodendrocytes have at least in animal models of demyelinating disease the potential for remyelination [66] .
Reprogramming cell fate has the exciting potential to tailor cell generation depending on the missing cell type. At the same time, all those approaches are currently rather invasive (e.g., virus-based overexpression of transcription factors) and thus relatively far away from clinical applications. But the experimental approaches currently tested in animal models of disease may identify novel routes how to replace lost neural cells in the human brain.
Transplantation of Neural Stem Cells and Their Progeny to the Injured Brain
Boosting endogenous NSC activity or targeting neural cells to redirect them towards a neuronal fate represent approaches to target endogenous cell sources for neural cell replacement and repair. In addition, the strategy to transplant either neuronal cells or their precursors has been investigated over the last decades and has been also clinically used [67, 68] . Transplantation-based approaches are probably most suitable for diseases in which selected neuronal subtypes are affected, such as dopaminergic neurons in PD or striatal interneurons in HD, and to a lesser extent when more widespread degeneration occurs, as for example in AD. In fact, clinical trials have been performed for PD in which dopaminergic precursor cells were isolated from the fetal mesencephalon followed by transplantation into the diseased brain. However, results were mixed [69] [70] [71] . As it turned out, one of the key factors in predicting the success of transplants was the quality and quantity of the transplant. Given that the cell source was fetal mesencephalic precursors (derived from aborted fetuses), restricting the availability and also containing progenitors for cells that may have adverse effects upon transplantation (e.g., GABAergic neurons), it became clear that a source of transplantable cells that is i) available at large quantities for standardization and ii) contains exactly the cell type required (in this case dopaminergic neurons/precursors) will be desirable [72] .
Substantial efforts have been undertaken in the last years to generate experimental protocols to yield pure dopaminergic neuronal populations derived from embryonic NSCs or pluripotent stem cells such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs). In fact, there are several promising approaches identified that at least in non-human primates showed exciting results in the context of PD models [58, 73, 74] . At this time new clinical trials are prepared that will use novel cell sources to test again the feasibility and efficacy of cell transplants to treat neurological disease [72] . This is not limited to PD but may also turn out to be applicable to other chronic degenerative diseases such as HD.
Perspectives and Conclusions
Regenerating the injured brain to allow for functional recovery remains a currently unmet challenge. Even though progress has been made in the last decades to ameliorate disease symptoms and to slow down disease progression for some diseases, the large majority of acute or chronic neurodegenerative diseases are still associated with substantial functional impairments in the everyday life of affected patients. Thus, novel approaches to regenerate the injured adult brain are needed [1] . The finding that NSCs persist in the adult brain and that neurogenesis occurs throughout life has spurred new hopes that the permissiveness of the adult brain to support life-long neurogenesis can be harnessed for repair. In addition, substantial progress has been made to understand the molecular and cellular mechanisms regulating neuronal differentiation and subsequent integration [75] .
Thus, it is probably realistic to hope that we will be able in the future to either recruit endogenous neurogenic cells such as NSCs or to reprogram neural cells into neurons. However, a key challenge will remain that neurons are not only generated but that they are capable to find their proper way into the preexisting circuit allowing for meaningful and correct integration. It is plausible to speculate that a wrongly integrated neuron or the wrong neuronal subtype may do more harm than improving brain function [76, 77] . Even though regional specifics are likely to exist, the adult brain gave us with the DG that harbors neurogenic NSCs under physiological conditions a system where we can study neuronal differentiation and integration of newborn neurons that apparently find their way into the circuit. In the future, we will have to understand more details how new neurons achieve this. These experiments will aim to discover more molecular details of adult neurogenesis, but we also need improved methods to study the process on a cellular level, e.g., using advanced imaging approaches to study the neurogenic process directly within the adult mammalian brain. The knowledge derived from these experiments will not only be important to develop strategies to recruit/activate endogenous neural cells for cell replacement. They will be also important to optimize transplantation-based approaches with the aim to achieve the best function of transplants in the adult brain. However, strategies aiming to transplant exogenous cells for brain repair will require further improved and optimized approaches to deliver cells safely and efficiently.
One apparent problem in the field is the dependence on animal models of acute or chronic diseases of the brain. This will not change, and in vivo experimental studies will remain a key pillar of brain regeneration research. However, the hope is that these experiments will be complemented in the future with approaches using human tissues grown in the culture dish that are derived from human NSCs or ESCs/iPSCs. Great progress has been made over the last years, and it became possible to grow organoids that resemble structurally at least early steps of brain development and that will allow for testing novel approaches directly in human cells/ tissues [78] . Such organoid-based approaches will need to be standardized and improved, but they may represent a novel direction allowing for faster translation of basic research into human treatment strategies. Potential applications are the use of human organoids to screen for compounds enhancing NSC activity or redirecting the fate of newborn cells. In combination with conventional experimental research using animal models of disease, the novel tools will hopefully bring us one step closer to achieve significant and functional brain regeneration in the future.
